La cadena de opciones muestra datos clave de las opciones de acciones de Mondee Hldgs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Mondee Hldgs..

Mondee Hldgs (NASDAQ:MOND) Bolsa, Cadena de Opciones

Mondee Hldgs

Mondee Holdings Inc is a travel technology company & marketplace with a portfolio of leisure & corporate travel sectors. The company provides AI platforms, technologies, operating systems, & services that enable travel transactions to serve travelers directly or through travel affiliates. The company has two segments Travel Marketplace & SAAS Platform. The Travel Marketplace segment consists of selling airline tickets through the proprietary platform. The SAAS Platform segment offers corporate travel cost savings solutions through its technology platform. The majority is from the Travel Marketplace segment. Geographically, the key revenue is from the United States.

Mondee Holdings, Inc. - Class A Common Stock

Mondee Holdings Inc

Mondi PLC ADR

Mondi PLC

Monday.Com Ltd

Monde Nissin Corp

Mondelez International, Inc. - Class A Common Stock

Mondelez International Inc

MONDIAL VNTRS INC by Mondial Ventures, Inc.

Mondial Ventures Inc

Elon Musk has expressed gratitude as major brands, including IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), and Warner Bros.&nbsp;Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>), resumed advertising on X, formerly Twitter.
What Happened: On Friday, Musk took to X and expressed his appreciation to companies for recommencing advertising on X following a <a href="https://www.benzinga.com/news/23/12/36056462/elon-musks-standoff-with-apple-disney-and-other-big-advertisers-forces-x-to-turn-to-smaller-ones">year-long boycott due to brand safety concerns</a>.
This information was shared by social media personality Mario Nawfal on X.
Musk responded to Nawfal's post,&nbsp;saying,&nbsp;&#8220;Just want to say that&nbsp;we super appreciate&nbsp;major brands resuming advertising on&nbsp;our platform!&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/41872302/taylor-swift-fans-abandon-elon-musks-x-for-bluesky-how-trumps-election-victory-triggered-swifties-uprising?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Taylor Swift Fans Abandon Elon Musk&#8217;s X For Bluesky, Says Report: How Trump&#8217;s Election Victory Triggered Swifties Uprising</a>
He also expressed&nbsp;his gratitude to&nbsp;X CEO Linda Yaccarino and&nbsp;the entire X team&nbsp;for restoring&nbsp;advertisers&#8217; confidence.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Just want to say that we super appreciate major brands resuming advertising on our platform! Thanks <a href="https://twitter.com/lindayaX?ref_src=twsrc%5Etfw">@lindayaX</a> and the whole &#120143; team for your hard work in restoring confidence in our platform and ensuring that advertising content only appears where advertisers want it shown. <a href="https://t.co/e508KrMo9g">https://t.co/e508KrMo9g</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1857471850676367646?ref_src=twsrc%5Etfw">November 15, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: In September, it was reported that more companies were <a href="https://www.benzinga.com/news/24/09/40762349/x-faces-major-advertiser-exodus-amid-string-of-elon-musk-controversies">considering pulling ads from X</a> next year due to concerns that their <a href="https://www.benzinga.com/news/23/11/35842015/ibm-pulls-adverts-from-elon-musks-x-following-antisemitic-content-allegations">brands could be harmed by the platform&#8217;s content</a>.
A Kantar survey also&nbsp;revealed that 26% more marketers&nbsp;plan to decrease their spending&nbsp;on X ads in 2025,&nbsp;marking the largest recorded decline&nbsp;in ad spending for any major global platform.
However, following the U.S. 2024 Presidential election, it was reported that some advertisers are contemplating a return to X to gain favor with Musk and President-Elect Donald Trump.
This development also comes as&nbsp;Meta Platforms Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) <a href="https://www.benzinga.com/general/social-media/24/11/41963996/mark-zuckerbergs-meta-eyes-2025-to-introduce-ads-on-threads-as-elon-musks-x-loses-favor-with-major-brands-report">plans to introduce ads</a> on its Threads early next year, potentially capitalizing on X&#8217;s loss of favor with major brands.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/41927135/greg-brockman-returns-to-work-at-chatgpts-parent-company-back-to-building-openai?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Greg Brockman Returns To Work At ChatGPT&#8217;s Parent Company: &#8216;Back To Building OpenAI&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

News

Social Media

Tech

CMCSA

IBM, Disney And Other Large Advertisers Return To Elon Musk's X After A Year-Long Boycott: 'We Super Appreciate'

The global plant-based Active Pharmaceutical Ingredient (API) market is projected to grow at a steady pace, reaching a valuation of $52.1 billion by 2034, according to a <a href="https://www.futuremarketinsights.com/reports/plant-based-api-market">new report</a> by Future Market Insights. The industry is expected to expand at a Compound Annual Growth Rate (CAGR) of 5.6%, fueled by rising demand for natural and sustainable pharmaceutical solutions, including <a href="https://www.benzinga.com/markets/psychedelics">psychedelics</a> and <a href="https://www.benzinga.com/topic/cannabis-products">cannabis-derived</a> compounds.
<h3 class="wp-block-heading">Rising Demand For Psychedelic And Cannabis-Based Ingredients</h3>
A significant driver of market growth is the increasing use of psychoactive and plant-derived substances in modern pharmacology. Psychedelics like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and cannabinoids such as <a href="https://www.benzinga.com/topic/cbd">CBD</a> and <a href="http://v">THC</a> are gaining attention for their <a href="http://v">therapeutic potential</a> in mental health and oncology. The U.S., a key player in the market, is leveraging biotechnological advances like <a href="https://www.genome.gov/genetics-glossary/CRISPR#:~:text=CRISPR%20(short%20for%20%E2%80%9Cclustered%20regularly,editing%20systems%20found%20in%20bacteria.">CRISPR</a> and synthetic biology to scale production of these high-demand APIs, contributing to a 4.2% CAGR.
"The global shift toward sustainable, plant-based solutions reflects both consumer interest in natural medicine and the pharmaceutical industry's focus on alternative therapies," said Sabyasachi Ghosh, associate VP at Future Market Insights. The market&#8217;s rapid expansion underscores the increasing acceptance of psychedelics and cannabis as mainstream pharmaceutical ingredients.
<h3 class="wp-block-heading">Therapeutic Applications And Key Botanical Sources</h3>
Plant-based APIs are harnessed from well-documented medicinal plants such as cannabis, ginseng, turmeric and cinchona. These natural sources contain bioactive compounds like flavonoids, terpenes and alkaloids, offering various therapeutic benefits. Major applications of plant-based APIs include pain management, anti-inflammatory treatments and oncology therapies.
The incorporation of cannabinoids, particularly CBD and THC, into pharmaceutical formulations is reshaping the landscape of pain and anxiety treatments. Similarly, psychoactive compounds from plants like Syrian rue and Psilocybe mushrooms are being explored for treating mental health disorders like depression and PTSD.
<h3 class="wp-block-heading">Regional Growth And Market Segmentation</h3>
The report highlights robust growth in Asian markets, with India leading at an 8.8% CAGR, followed closely by China (8.7%) and South Korea (8.6%). These regions are investing heavily in agricultural biotechnologies and expanding their capabilities in plant-based pharmaceutical production.
The market segments by product type, covering alkaloids, cannabinoids, <a href="https://www.benzinga.com/markets/cannabis/24/05/39064102/cannabis-terpenes-alleviate-chemo-induced-neuropathic-pain-study-shows-added-benefits-with-morph">terpenes</a>, flavonoids and polyphenols. It also includes API forms like extracts, powders and resins from botanicals such as opium poppy, turmeric, ginseng and cannabis.
<h3 class="wp-block-heading">Competitive Landscape: Psychedelics And Cannabis Companies Lead the Charge</h3>
The plant-based API sector is experiencing intense competition, particularly in the cannabis and psychedelics segments. Companies are rapidly scaling production and forming key partnerships to meet the rising demand for plant-based, pharmaceutical-grade ingredients.
Recent developments include Bright Green Corporation's agreement to supply <a href="https://www.benzinga.com/24/02/37292778/dea-clears-this-nasdaq-traded-plant-touching-firm-to-research-and-produce-schedule-i-and-ii-plant-ba">DEA-approved marijuana</a> extracts and psychedelic compounds to Benuvia Operations. Indena's authorization from Italian regulators to produce pharmaceutical-grade CBD further illustrates the expanding global footprint of cannabis-derived APIs.
Key players in the industry include the Illinois-based Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), New Mexico&#8217;s Bright Green Corporation, Indena S.p.A., headquartered in Milan, Italy, Alchem International Pvt. Ltd., based in India, Israeli Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>); Roquette Frères, based in Lestrem, France; and Sami-Sabinsa Group, based in New Jersey.
<h3 class="wp-block-heading">The Future Of Plant-Based APIs: Sustainable And Psychedelic Solutions</h3>
The growing demand for sustainable, natural treatments will likely position the plant-based API market at the forefront of global healthcare. As pharmaceutical companies continue to explore the therapeutic potential of bioactive compounds from plants, the integration of psychedelics and cannabis-derived APIs is likely to play a pivotal role in shaping the next decade of medicine.
Cover image made with AI

Cannabis

Market Summary

Psychedelics

Global

Markets

TEVA

Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids

SpaceX, under the leadership of Elon Musk, is reportedly preparing to initiate a tender offer next month.
What Happened: SpaceX's tender offer will allow the sale of existing shares at $135 each, valuing the company at over $250 billion, as reported by Reuters.
Musk&#8217;s ambition for human Mars exploration could become a national priority under Trump&#8217;s administration. The NASA Artemis program, which intends to use SpaceX&#8217;s Starship for lunar missions as a precursor to Mars expeditions, is anticipated to shift focus towards Mars with uncrewed missions targeted this decade.
SpaceX might push for relaxed regulations on worker and participant safety in private space flights under Trump&#8217;s presidency.
An investigation last year revealed over 600 worker injuries at SpaceX facilities, <a href="https://www.benzinga.com/news/24/04/38374353/elon-musks-spacex-injury-rates-exceed-industry-average-again-raising-concerns-for-nasa-and-clients-r">exceeding the industry average</a>, raising concerns about the company&#8217;s adherence to safety standards.
See Also: <a href="https://www.benzinga.com/trading-ideas/24/11/41985486/if-tesla-stock-hits-all-time-highs-in-2025-will-it-be-driven-by-trump-musk-relationship-benzinga-readers-say-this?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">If Tesla Stock Hits All-Time Highs In 2025, Will It Be Driven By Trump-Musk Relationship?</a>
Why It Matters: SpaceX&#8217;s valuation has seen a significant increase over the past year. In June, the company was reportedly set for a <a href="https://www.benzinga.com/news/24/06/39516906/elon-musks-spacex-set-for-record-210b-valuation-in-tender-offer-but-still-valued-less-than-tiktok-re">record $210 billion</a> valuation in a tender offer, surpassing its previous $200 billion estimate. This was driven by substantial investor demand.
However, Musk has <a href="https://www.benzinga.com/news/24/06/39519229/elon-musk-dismisses-rumors-of-spacex-ipo-as-it-reportedly-seeks-210b-valuation-pressure-for-short-te">previously dismissed</a> the possibility of a SpaceX initial public offering (IPO), citing the intense pressure for short-term results faced by publicly listed companies.
SpaceX&#8217;s dominance in the space sector is further highlighted by its control over <a href="https://www.benzinga.com/news/24/09/40869627/elon-musk-now-controls-two-thirds-of-the-planets-satellites-and-spacex-is-just-getting-started-with">two-thirds of the planet&#8217;s satellites</a>, thanks to the rapid expansion of its Starlink satellite network.
As of September, SpaceX&#8217;s Starlink service <a href="https://www.benzinga.com/news/24/09/41061483/spacexs-starlink-now-connects-4m-customers-with-more-than-6k-operational-satellites-adds-a-million-u">connects over 4 million customers</a> worldwide, demonstrating the company&#8217;s significant impact on global connectivity.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41973501/teslas-profit-power-vs-rivians-cash-burn-can-the-gap-be-narrowed?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla&#8217;s Profit Power Vs. Rivian&#8217;s Cash Burn: Can The Gap Be Narrowed?</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

SPACE

Startups

SpaceX To Launch Tender Offer, Valuing Company At Over $250 Billion: Report

A major cyber-espionage operation linked to Chinese intelligence has reportedly infiltrated T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) and other telecom giants, including rivals AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) and Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) <a href="https://www.benzinga.com/news/24/10/41200026/chinese-hackers-breach-at-t-verizon-networks-in-major-wiretap-data-theft-putting-us-national-securit">suffered a similar breach</a>, raising significant national security concerns.
What Happened: T-Mobile&#8217;s network was compromised in a large-scale cyber-espionage operation attributed to Chinese hackers, according to a <a href="https://www.wsj.com/politics/national-security/t-mobile-hacked-in-massive-chinese-breach-of-telecom-networks-4b2d7f92">report</a> by The Wall Street Journal.
This breach, which also affected other U.S. and international telecom companies, targeted cellphone communications of high-value intelligence targets.
The extent of the data compromised from T-Mobile customers remains uncertain.
"T-Mobile systems and data have not been impacted in any significant way, and we have no evidence of impacts to customer information," said a T-Mobile spokesperson, according to the report.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41939983/microsoft-president-warns-beijings-tech-progress-is-catching-up-with-the-west-people-who-dont-go-to-china-too-often-assume-theyre-behind?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Microsoft President Warns Beijing&#8217;s Tech Progress Is Catching Up With The West</a>
The breach, linked to the Salt Typhoon group, is considered historic in its scope and severity by some U.S. officials. AT&amp;T, Verizon, and Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) were also reportedly affected.
Hackers exploited vulnerabilities in Cisco Systems routers and possibly used AI or machine learning to enhance their operations, accessing cellphone lines of senior U.S. government and political figures.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: This breach is part of a series of cyberattacks attributed to Chinese hackers, raising alarms about national security.
In April, FBI Director Christopher Wray warned about <a href="https://www.benzinga.com/news/24/04/38330156/fbi-chief-warns-xi-jinpings-ccp-linked-chinese-hackers-are-planning-to-physically-wreak-havoc-on-us">China&#8217;s potential to disrupt U.S. infrastructure</a>, highlighting the targeting of sectors like telecommunications, energy, and water.
In May, a <a href="https://www.benzinga.com/news/24/05/38659657/major-hacking-incident-exposes-data-of-military-personnel-in-uk-ministry-of-defence-breach-is-china">major hacking incident</a> exposed data of U.K. military personnel, with China suspected as the perpetrator.
The recent breach of T-Mobile and other telecom giants underscores the ongoing threat posed by state-sponsored cyber-espionage, emphasizing the need for heightened cybersecurity measures.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42022077/elon-musks-xai-seeks-6b-at-50b-valuation-to-acquire-100k-nvidia-chips-for-memphis-data-center">Elon Musk&#8217;s xAI Seeks $6B At $50B Valuation To Acquire 100K Nvidia Chips For Memphis Data Center</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Unsplash

LUMN

TMUS

T-Mobile Hit By Chinese Hackers After Rivals AT&T, Verizon Suffer Breach: Report

ARC Global Investments, a major investor in&nbsp;Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), has drastically reduced its stake in the company.
What Happened: According to a regulatory filing on Friday, ARC Global and its manager, Patrick Orlando, now hold a mere 0.01% stake in Trump Media, the parent company of&nbsp;Truth Social.
This is a significant decrease from their previous holding of over 5% or more than&nbsp;11 million shares in September.
Orlando, the former CEO of Digital World Acquisition Corp., the SPAC that took Trump Media public, was <a href="https://www.benzinga.com/news/23/03/31451246/trump-linked-spac-digital-world-boots-out-ceo-as-it-looks-to-bring-in-new-management-to-tackle-unpre">removed from his role</a> before the deal was completed.
See Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/24/11/41927985/bitcoin-ethereum-consolidate-dogecoin-surges-as-election-rally-takes-a-breather-analyst-says-pullback-typical-for-healthy-market?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum Consolidate, Dogecoin Surges As Election Rally Takes A Breather: Analyst Says Pullback &#8216;Typical&#8217; For Healthy Market</a>
In July, the U.S. Securities and Exchange Commission (SEC) sued Orlando, <a href="https://www.benzinga.com/news/24/07/39829953/trump-linked-digital-worlds-former-ceo-sued-by-sec-for-securities-fraud">alleging securities fraud</a> for false and misleading statements as CEO of Digital World Acquisition.
In September, a Delaware judge ruled that Trump Media had violated an agreement with ARC Global. The ruling stated that the fund should receive over&nbsp;half a million additional shares&nbsp;before the expiration of&nbsp;a lock-up on insider sales.
Why It Matters: President-elect Donald Trump&nbsp;currently holds&nbsp;a <a href="https://www.benzinga.com/markets/equities/24/11/41878254/trumps-djt-surges-26-in-past-month-boosting-investors-wealth-by-over-1b-as-ex-president-returns-to-white-house-for-a-second-term">57% stake in&nbsp;Trump Media</a>.
On Election Day, Trump Media reported a 6% year-over-year decrease in its <a href="https://www.benzinga.com/news/earnings/24/11/41760961/djt-stock-volatile-on-election-day-donald-trumps-media-company-reports-q3-earnings-growth-initiativ">third-quarter net sales</a>, which stood at $1.01 million, with all revenue coming from advertising on the Truth Social platform.
Earlier this month, Trump announced that he had no plans to <a href="https://www.benzinga.com/media/24/11/41853221/trump-says-he-wont-sell-trump-media-stock">sell his stake in the Truth Social parent</a>, causing the company&#8217;s stock to soar.
Meanwhile, on Wednesday, it was reported that <a href="https://www.benzinga.com/general/social-media/24/11/41993328/trump-media-insiders-sell-more-than-16-million-in-djt-stock">Trump Media&#8217;s CFO</a> and two other insiders sold millions of dollars worth of shares following the election.
Price Action: DJT shares ended Friday up 4.11%, closing at $28.10. However, in after-hours trading, the stock dipped 0.57% to $27.94 at the time of writing, according to <a href="https://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41964758/trumps-attorney-general-pick-matt-gaetz-once-proposed-collecting-federal-income-taxes-in-bitcoin-apart-from-co-sponsoring-bill-to-abolish-the-fed?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Attorney General Pick Matt Gaetz Once Proposed Collecting Federal Income Taxes In Bitcoin, Apart From Co-sponsoring Bill To Abolish The Fed</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Major Investor In Trump Media Offloads Most Of Its Stake In DJT Stock

Elon Musk&#8217;s artificial intelligence venture, xAI, is reportedly in the process of raising up to $6 billion. The funds are intended for purchasing 100,000 Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips.
What Happened: xAI's latest funding round is expected to close early next week, as reported <a href="https://www.cnbc.com/2024/11/15/elon-musks-xai-raising-up-to-6-billion-to-purchase-100000-nvidia-chips-for-memphis-data-center.html">by</a> CNBC on Friday. It includes $5 billion from Middle Eastern sovereign funds and an additional $1 billion from other investors. Some of these investors may be looking to increase their stakes.
This fundraising would value Musk's AI startup at $50 billion, more than doubling the $24 billion valuation in its <a href="https://www.benzinga.com/news/24/05/39025708/elon-musk-cheers-funding-after-xai-secures-6b-from-sequoia-andreessen-horowitz-saudi-prince-alwaleed">previous round of funding in May</a>.
The chips are crucial for the new Memphis supercomputer, which will support Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Full Self-Driving (FSD) technology.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
xAI, launched in July 2023, aims to &#8220;understand the true nature of the universe,&#8221; according to its website.
Last year, xAI introduced a chatbot named Grok, inspired by &#8220;The Hitchhiker&#8217;s Guide to the Galaxy.&#8221; The chatbot was designed to compete with OpenAI&#8217;s ChatGPT, Google&#8217;s Gemini, and Anthropic&#8217;s Claude.
See Also: <a href="https://www.benzinga.com/24/11/41872302/taylor-swift-fans-abandon-elon-musks-x-for-bluesky-how-trumps-election-victory-triggered-swifties-uprising?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Taylor Swift Fans Abandon Elon Musk&#8217;s X For Bluesky, Says Report</a>
Why It Matters: Earlier this year, <a href="https://www.benzinga.com/news/24/05/39027735/elon-musks-xai-raises-6b-heres-where-it-stands-against-openai-anthropic-and-other-ai-rivals">xAI raised $6 billion</a> in its Series B funding round, catapulting its valuation to $24 billion.
This positioned xAI among the world&#8217;s most valuable AI startups, alongside giants like Microsoft Corp.-backed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) OpenAI and Anthropic. Despite this, xAI is not yet the largest AI startup in terms of valuation.
The <a href="https://www.benzinga.com/news/24/06/39199007/elon-musks-xai-to-take-on-tech-giants-microsoft-google-and-openai-with-planned-memphis-supercomputer">planned Memphis supercomputer</a>, a key component of xAI&#8217;s strategy, is set to enhance its AI capabilities. The project, located at a former manufacturing site, is awaiting approval from local authorities. Discussions with city officials began in March, underscoring the competitive nature of securing such high-profile projects.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/24/11/41964846/openais-operator-ai-agent-will-perform-tasks-like-coding-travel-booking-and-more-launch-expected-in-january-next-year-report">OpenAI&#8217;s &#8216;Operator&#8217; AI Agent Will Perform Tasks Like Coding, Travel Booking And More</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

MSFT

NVDA

TSLA

Elon Musk's xAI Seeks $6B At $50B Valuation To Acquire 100K Nvidia Chips For Memphis Data Center

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BJDX

SMST

LIFW

SMCX

LIFWW

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

Earnings

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Generally, when the masses &ndash; including the market&rsquo;s heavy hitters &ndash; decide to bet against a security, it&rsquo;s best to avoid it. However, the unique nuances involved with shorting a company opens the door for the contrarian trade. To be sure, so-called short-squeeze stocks to buy are incredibly risky. Yet at the same time, they also present significant upside potential.



When you go long a company, you&rsquo;re obviously hoping that you can buy low and sell high. However, when you short an enterprise, you&rsquo;re aiming to sell high so that you can buy low later and profit from the difference. To initiate a pure short position requires first borrowing (setting aside the exception of naked short selling) the target stock from a broker.



That&rsquo;s where circumstances get interesting. If the underlying security falls in value, a short position can be incredibly lucrative. However, if shares rise, the bearish speculator ends up losing money. Not only that, no upside ceiling exists for any stock. Therefore, it&rsquo;s critical to cut losses early.



The panic to exit early is what creates the upside pressure undergirding short-squeeze stocks to buy. It&rsquo;s a risky business but it&rsquo;s oh so tempting.



<h2>Nuvalent (NUVL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div>One of the most heavily targeted securities, Nuvalent (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuvl-stock-quote/">NUVL</a>) falls under the biotechnology sphere. Specifically, it&rsquo;s a clinical-stage biopharmaceutical firm that engages in the development of therapies for patients with cancer. Notably, NUVL stock has gained 79% in the past 52 weeks. Since making its public market debut, the company gained around 330% of equity value.



That said, skeptics have entered the fray. Presently, NUVL represents one of the most targeted securities, with a <a href="https://fintel.io/ss/us/nuvl">short interest</a> of 20.29% of its float. Typically, any magnitude of short interest <a href="https://www.investopedia.com/terms/s/shortinterest.asp#:~:text=Yes.-,Short%20interest%20as%20a%20percentage%20of%20float%20above%2020%25%20is,indicates%20a%20very%20pessimistic%20sentiment.">above 20%</a> is considered to be high. Further, NUVL&rsquo;s short interest ratio &ndash; or the time required to unwind all bearish positions based on average trading volume &ndash; stands at 38.89 days to cover.



Based on that information, it seems like bad news for Nuvalent. However, the company could rank among the short-squeeze stocks to buy. Analysts rate NUVL a <a href="https://www.tipranks.com/stocks/nuvl/forecast">unanimous strong buy</a> with a $98.80 average price target. That implies a 26% upside potential.



Financially, experts anticipate that in fiscal 2025, sales could hit $$530,000, with a high-side view of $4.8 million. That would be massive as Nuvalent is presently a pre-revenue entity.



<h2>Mondee (MOND)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/air-travel-1600-300x169.png" alt="Plane travel. Man standing in airport waiting for flight. travel stocks to buy"><div>Source: Olena Yakobchuk / Shutterstock</div></div>Based in Austin, Texas, Mondee (NASDAQ:<a href="https://investorplace.com/stock-quotes/mond-stock-quote/">MOND</a>) falls under the consumer cyclical sector. Specifically, it provides travel services. The company&rsquo;s mainline business unit offers airline tickets through its platform. It also provides a Software as a Service (SaaS) model that facilitates corporate travel cost savings solutions. With people prioritizing vacations in the post-pandemic era, MOND stock should attract bullish attention.



However, that hasn&rsquo;t been the case at all. Since the beginning of the year, MOND slipped 18%. In the past 52 weeks, shares stumbled a staggering 75.5%. Not surprisingly, then, the bears began circling the waters. Short interest comes in at <a href="https://fintel.io/ss/us/mond">20.64% of the float</a>. Further, the short-interest ratio stands at 56.17 days to cover.



Still, not all hope is lost, at least for the optimists. Analysts rate Mondee a <a href="https://www.tipranks.com/stocks/mond/forecast">consensus moderate buy</a> with a $4.18 average price target, implying over 95% upside potential. Further, with the downside, MOND could be priced at a more enticing valuation. Shares trade at 0.69X trailing-year revenue. That&rsquo;s down from 1.21X in the fourth quarter of last year.



Experts also anticipate 14.8% growth in the top line to $255.09 million in fiscal 2024. So, MOND could be one of the short-squeeze stocks to buy.



<h2>Zynex (ZYXI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/healthcare-1600-300x169.jpg" alt="Nurse holding a tablet with icons representing different aspects of healthcare and healthcare data representing CANO stock. Healthcare Tech Stocks. Healthcare Stocks to Buy"><div>Source: metamorworks / Shutterstock</div></div>Headquartered in Englewood, Colorado, Zynex (NASDAQ:<a href="https://investorplace.com/stock-quotes/zyxi-stock-quote/">ZYXI</a>) falls under the broader healthcare sector, specifically medical distribution. With its subsidiaries, Zynex designs, manufactures and markets medical devices to treat chronic and acute pain. Its primary focus is in the area of electrical stimulation for rehabilitative purposes. The business sounds incredibly relevant yet the market has other ideas.



Since the start of the year, ZYXI slipped almost 16%. The volatility has been pronounced in the past month, when shares gave up 13% of market value. Zynex has also gone nowhere in the trailing five years, thereby frustrating longtime stakeholders. As a result, the company&rsquo;s <a href="https://fintel.io/ss/us/zyxi">short interest</a> soared to 36.89% of the float. Also, the short-interest ratio jumped to 53.44 days to cover.



Obviously, that&rsquo;s not a great outcome. However, ZYXI could be one of the short-squeeze stocks to buy. It presently enjoys a consensus view of <a href="https://www.tipranks.com/stocks/zyxi/forecast">moderate buy</a>. Also, the price target stands at $18, implying 96% upside potential.



Financially, experts anticipate the company&rsquo;s sales in fiscal 2024 to rise to $226.95 million. If so, that would imply growth of 23.1%.



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/3-short-squeeze-stocks-poised-for-a-jaw-dropping-rally/">3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Short-squeeze stocks represent one of the boldest forms of contrarianism available. Simply put, it&rsquo;s a showdown between the bears that are attempting to profit from the downturn of a public enterprise. In their minds, by eliminating weak players from the market, it improves Wall Street&rsquo;s &ldquo;gene pool,&rdquo; if you will. On the other end, the bulls can play the savior role.



What makes short-squeeze stocks so compelling, though, is the incentivization profile. On the pessimistic side, speculators make their money pocketing the difference between the borrowed securities selling price versus the subsequent buy-back price. If the latter is lower than the former, the trader picks up a profit. However, if the latter is higher, than the speculator incurs a loss.



Now, unlike other types of market losses, the red ink on a short trade is uncapped. That&rsquo;s because there&rsquo;s no limit to how high a security can rise. Therefore, a panic to cover bearish positions (by buying to close) can yield a dramatic lift in the share price, called a short squeeze. With that in mind, below are short-squeeze stocks to consider.



<h2>Kadant (KAI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/07/short-squeeze-stocks-300x169.jpg" alt="Man squeezing water out of a rag representing FNGR stock. Short Squeeze Stocks"><div>Source: Alextype/Shutterstock.com</div></div>Operating in the specialty industrial machinery sector, Kadant (NYSE:<a href="https://investorplace.com/stock-quotes/kai-stock-quote/">KAI</a>) supplies various technologies and engineered systems worldwide. Primarily, the company focuses on fluid-handling systems and equipment, such as rotary joints and syphons. It also features other relevancies, including innovations in industrial automation and control. Still, KAI has fluctuated in market value.



Nevertheless, investors will want to keep close tabs on Kadant. According to Fintel, KAI stock carries a <a href="https://fintel.io/ss/us/kai">short interest of 12.32% of its float</a>. That&rsquo;s elevated but not intensely remarkable. However, the equity unit&rsquo;s short-interest ratio stands at nearly 33 days to cover. That&rsquo;s the number of trading sessions it would take for the bears to close out their short exposure.



If a panic materializes, the bears will be anxious to seal off their vulnerability. They&rsquo;re even more motivated to do this with Kadant, noting that KAI stock has gained 13% in the trailing month. In addition, the company is projected to see revenue growth of nearly 11% to $1.06 billion by year&rsquo;s end. It&rsquo;s one of the short-squeeze stocks to consider.



<h2>AirSculpt Technologies (AIRS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/oversold-stocks-to-buy-300x169.jpg" alt="man in suit holding a tablet with graphic above showing oversold stocks to buy"><div>Source: undefined undefined / Getty Images</div></div>Operating in the medical care facilities industry, AirSculpt Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/airs-stock-quote/">AIRS</a>) along with its subsidiaries provides body contouring procedure services. It offers its namesake solution, which is a next-generation body contouring protocol that removes unwanted fat and tightens skin. Best of all, the procedure is minimally invasive.



Still, many investors are skeptical about AIRS stock. Since the start of the year, shares tumbled more than 36%. As a result, the<a href="https://fintel.io/ss/us/airs"> short interest of AirSculpt comes in at 16.26% of its float</a>. However, the short-interest ratio is truly remarkable, standing at almost 56 days to cover. We&rsquo;re basically talking business days here so that&rsquo;s a lengthy period of vulnerability for the bears.



If AIRS stock starts shooting higher for whatever reason, a panic could easily materialize. It&rsquo;s worth pointing out that in the business week ended July 12, the equity gained more than 16%. In addition, analysts project that AirSculpt can post earnings per share of 24 cents this year. That&rsquo;s up from last year&rsquo;s loss of 8 cents. It&rsquo;s a candidate for short-squeeze stocks.



<h2>Trupanion (TRUP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/trup1600-300x169.jpg" alt="a veterinarian holding a small white dog"><div>Source: Shutterstock</div></div>Falling under the specialty insurance segment, Trupanion (NASDAQ:<a href="https://investorplace.com/stock-quotes/trup-stock-quote/">TRUP</a>) in my opinion represents a clear-cut case for short-squeeze stocks. With its subsidiaries, Trupanion provides medical insurance for cats and dogs on a monthly subscription basis. What&rsquo;s enticing here is the fundamental catalyst: Americans (and citizens of other countries) love their pets.



It&rsquo;s too bad that Wall Street doesn&rsquo;t love TRUP stock. Since the beginning of this year, shares gained less than 2%. Over the past five years, it went nowhere if you had held throughout the entire period: TRUP lost a bit more than 9%. Still, what&rsquo;s intriguing here is that the equity&rsquo;s <a href="https://fintel.io/ss/us/trup">short interest</a> stands at nearly 33% of its float. Further, the short-interest ratio is 31.41 days to cover.



If you&rsquo;re an extreme contrarian, these figures may have you drooling. What you have is an extremely high short interest along with a blisteringly hot short ratio. You&rsquo;ve basically got the bears boxed in if the position moves against them. Analysts are calling for revenue to expand by 13.7% to $1.26 billion in fiscal 2024.



<h2>Westrock Coffee (WEST)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/09/coffee_1600-300x169.jpg" alt="NUZE Stock. A photo of a cup of coffee and some coffee beans and a towel on a wooden table. Coffee stocks"><div>Source: Evgeny Karandaev/ShutterStock.com</div></div>Falling under the consumer defensive space, Westrock Coffee (NASDAQ:<a href="https://investorplace.com/stock-quotes/west-stock-quote/">WEST</a>) operates in the packaged foods industry. <a href="https://finance.yahoo.com/quote/WEST/profile/">Per its public profile</a>, Westrock is an integrated coffee, tea, flavors, extracts and ingredients provider. It mainly serves the U.S. though it also covers other international markets. With the growing demand for coffee worldwide, WEST stock should be intriguing for many investors.



Unfortunately, Wall Street doesn&rsquo;t have much love for Westrock. Since the beginning of January, shares lost about 2% of equity value. In the past 52 weeks, they&rsquo;re down 8%. Those aren&rsquo;t great statistics. At the same time, contrarian investors should consider the bearish profile. Short interest stands at a whopping 54.85%. That&rsquo;s extreme and then some. Also, the short ratio hits 33.27 days to cover.



Again, what we have here is a situation where the bears are locked in. If the position moves against them, a big panic can materialize. After all, 33 business days is a long time. Plus, experts project 9.4% sales growth to $945.67 million this year. It&rsquo;s one of the short-squeeze stocks to consider.



<h2>Mondee Holdings (MOND)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/air-travel-1600-300x169.png" alt="Plane travel. Man standing in airport waiting for flight. travel stocks to buy"><div>Source: Olena Yakobchuk / Shutterstock</div></div>Operating in the consumer cyclical sector, Mondee Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/mond-stock-quote/">MOND</a>) specifically covers the travel services realm. <a href="https://finance.yahoo.com/quote/MOND/profile/">Per its corporate profile</a>, Mondee operates as a travel technology firm for the leisure travel space. Primarily, the company focuses on the sale of airline tickets through its platform. Thanks to people prioritizing their vacation time post-pandemic, MOND stock should be intriguing.



However, the market has had a tough time deciphering what the underlying business is all about. On a year-to-date basis, MOND incurred a loss of more than 3%. Further, the trading action has been incredibly choppy throughout 2024 so far. Still, MOND could attract contrarians with its short interest of just under 21% of its float. Further, the short interest ratio stands at 42.58 days to cover.



As with so many of the other short-squeeze stocks on this list, an upside panic can lead to more upside as the bears rush to cover their short positions. Experts also see Mondee hitting $255.09 million in sales for fiscal 2024, implying 14.8% growth from last year.



<h2>scPharmaceuticals (SCPH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div>Falling under the biotechnology space, scPharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/scph-stock-quote/">SCPH</a>) engages in the development and commercialization of various pharmaceutical products. Its lead <a href="https://finance.yahoo.com/quote/SCPH/profile/">product candidate is Furoscix</a>, which aims to treat congestion due to fluid overload in adults with chronic heart failure and kidney disease. Given the <a href="https://www.cdc.gov/pcd/issues/2024/23_0267.htm#:~:text=Over%20the%20past%202%20decades,at%20least%205%20(5).">rise of incidences of chronic disease</a>, scPharmaceuticals should &ldquo;benefit&rdquo; (for lack of a better word) from this dynamic.



However, the market seems to have other ideas. Since the start of the year, SCPH stock incurred a loss of more than 29%. In the past 52 weeks, it&rsquo;s down almost 47%. Still, this could be a case of bad news being good news, especially for contrarians. <a href="https://fintel.io/ss/us/scph">The short interest of SCPH stands at 36% of its float</a>. Also, the short-interest ratio clocks in at 50.5 days to cover.



If shares start flying higher, the bears could be locked in. Therefore, the contrarian bulls are possibly licking their lips. Analysts believe that the biotech could post sales of $39.34 million this year. If so, that would imply a growth rate of 189.4%. This is one of the more tempting short-squeeze stocks.



<h2>Verrica Pharmaceuticals (VRCA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/12/vrca1600-300x169.png" alt="Shot of Sterile Pharmaceutical Manufacturing Laboratory where Scientists in Protective Coverall's Do Research, Quality Control and Work on the Discovery of new Medicine. VRCA stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Ending this list with another healthcare-related entity, Verrica Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrca-stock-quote/">VRCA</a>) is a clinical-stage dermatology therapeutics firm. It develops medications for the treatment of skin diseases. Right now, it features a therapeutic called Ycanth (VP-102), which is in Phase 3 trials for the treatment of common warts. Given the sensitive needs to address such skin conditions, Verrica should be a top player.



Sure enough, VRCA stock has gained over 25% of market value since the start of the year. However, it&rsquo;s been a choppy ride. Those who got in during this year&rsquo;s highs are still underwater, implying lingering pessimism. This dynamic explains the <a href="https://fintel.io/ss/us/vrca">high short interest</a> of 26%. Not only that, VRCA&rsquo;s short interest ratio lands at 32.83 days to cover.



However, if shares start swinging higher for whatever reason, the bears would likely find themselves in trouble. It takes a while to unwind a short ratio of 33 days. Further, analysts anticipate massive growth in the coming years. Fiscal 2024 sales could hit $24.71 million, up 382.2%. And fiscal 2025 may see revenue up at $70.3 million. It&rsquo;s one of the short-squeeze stocks to keep on your radar.



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/7-short-squeeze-stocks-that-could-beat-down-the-bears/">7 Short-Squeeze Stocks That Could Beat Down the Bears</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Short-Squeeze Stocks That Could Beat Down the Bears

Mondee Holdings (MOND – Research Report), the Consumer Cyclical sector company, was revisited by a Wall Street analyst today. Analyst Darren Aftahi...

Buy Rating Affirmed for Mondee Holdings Amid Debt Restructuring and Strategic Growth Initiatives

Mondee Holdings Non-GAAP EPS of -$0.17 misses by $0.11, revenue of $58.33M misses by $3.12M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Mondee Hldgs (NASDAQ:<a href="https://investorplace.com/stock-quotes/mond-stock-quote/">MOND</a>) just reported results for the second quarter of 2024.<ul><li>Mondee Hldgs reported earnings per share of -17 cents. This was below the analyst estimate for EPS of -15 cents.</li><li>The company reported revenue of $58.33 million.</li><li>This was 5.08% worse than the analyst estimate for revenue of $61.45 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mond-stock-earnings-mondee-hldgs-for-q2-of-2024/">MOND Stock Earnings: Mondee Hldgs Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MOND Stock Earnings: Mondee Hldgs Misses EPS, Misses Revenue for Q2 2024

Mondee Holdings, Inc. (MOND) Q2 2024 Earnings Call Transcript

Mondee Holdings (MOND) has issued an update. Mondee Holdings, Inc. has amended its financial agreements to extend the maturity of its loans and cre...

Mondee Holdings Revamps Financial Strategy Until 2028

In a report released today, Darren Aftahi from Roth MKM maintained a Buy rating on Mondee Holdings (MOND – Research Report), with a price target of...

Mondee Holdings' Strengthened Financial Position: A Buy Rating by Darren Aftahi

An announcement from Mondee Holdings ( ($MOND) ) is now available. Mondee Holdings, Inc. has successfully renegotiated the terms of its financing, ...

Mondee Holdings Bolsters Growth with Strategic Financial Restructuring

Mondee Needs Much More Financing To Mature Its Business, And Shareholders Face Dilution Ahead

AIRS

MOND

NUVL

SCPH

TRUP

VRCA

WEST

ZYXI

Press Releases

Mondee Reports Preliminary Unaudited Q4 & FY 2023 Results

Mondee to Report First Quarter 2024 Financial Results on May 10, 2024

Mondee Reports First Quarter 2024 Results

Mondee to Report Second Quarter 2024 Financial Results on August 8, 2024

Mondee to Hold Webcast on Second Quarter 2024 Financial Results and Anticipated New Financing on August 14, 2024

Mondee Reports Second Quarter 2024 Results and Announces Comprehensive Long-Term Refinancing of its Capital Structure

Financing

Mondee Finalizes Long-Term Extensions of Term Loan and Preferred Equity with Receipt of $15M Letter of Credit

Mondee to Hold Webcast on Third Quarter 2024 Financial Results on November 8, 2024

Mondee Reschedules Webcast on Third Quarter 2024 Financial Results to November 12, 2024

Mondee Reschedules Webcast on Third Quarter 2024 Financial Results to November 18, 2024

Atour Lifestyle Holdings Limited - American Depositary Shares

Atour Lifestyle Holdings

Despegar.com

Global Business Travel Group, Inc. Class A Common Stock

Global Business Travel

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

Comments

Mondee Hldgs

Mondee Hldgs (MOND) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL